Work With Us
Contact Us
Work With Us
Contact Us
Search
Home
About Us
Our Mission and Vision
Meet the Team
Senior Management
Board of Directors
Scientific Advisory Board
Investors
Our Science
About Macrocycles
Introducing MXMO
TM
Our Pipeline
Clinical Trials
What’s New
Press Releases
Publications
Events
Home
About Us
Our Mission and Vision
Meet the Team
Senior Management
Board of Directors
Scientific Advisory Board
Investors
Our Science
About Macrocycles
Introducing MXMO
TM
Our Pipeline
Clinical Trials
What’s New
Press Releases
Publications
Events
Publications
Publications
AACR 2026: Discovery of CID-078, a first-in-class oral macrocycle cyclin A/B-RxL inhibitor, for the treatment of cancers with Rb-deficiency or hyperactivated E2F
April 20, 2026
Click here
Publications
AACR 2026: Early clinical activity from the phase 1 evaluation of CID-078, a novel cyclin A/B RxL inhibitor, in patients with advanced solid tumors
April 19, 2026
Click here
Publications
AACR 2026: Orally bioavailable peptide macrocycles disrupting intracellular protein-protein interactions: selective inhibitors of the RxL binding site of cyclin family proteins
April 18, 2026
Click here
Publications
AACR-NCI-EORTC 2025: First-in-class oral macrocyclic cyclin D1-selective inhibitors demonstrate anti-tumor activity in cyclin D1-dependent tumors
October 23, 2025
Click here
Publications
AACR Conference on Pediatric Cancer: Investigating the cyclin A/B RxL inhibitor CID-078 in pediatric cancers with RB1 loss and high E2F1
October 1, 2025
Click here
Publications
Nature: Targeting G1–S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors
August 20, 2025
Click here
LOAD MORE
Sign up to stay informed
SUBSCRIBE
Subscribe to our News Alerts
By checking the box and pressing the subscribe button , I acknowledge and accept Circle Pharma’s
Privacy Policy
and
Terms of Service.
Subscribe
